JPWO2020252014A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020252014A5
JPWO2020252014A5 JP2021573428A JP2021573428A JPWO2020252014A5 JP WO2020252014 A5 JPWO2020252014 A5 JP WO2020252014A5 JP 2021573428 A JP2021573428 A JP 2021573428A JP 2021573428 A JP2021573428 A JP 2021573428A JP WO2020252014 A5 JPWO2020252014 A5 JP WO2020252014A5
Authority
JP
Japan
Prior art keywords
composition
ketoglutarate
composition according
calcium alpha
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537685A (ja
JP7751291B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036987 external-priority patent/WO2020252014A1/en
Publication of JP2022537685A publication Critical patent/JP2022537685A/ja
Publication of JPWO2020252014A5 publication Critical patent/JPWO2020252014A5/ja
Priority to JP2025080904A priority Critical patent/JP2025124683A/ja
Application granted granted Critical
Publication of JP7751291B2 publication Critical patent/JP7751291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573428A 2019-06-10 2020-06-10 アルファ－ケトグルタル酸塩の持続放出組成物 Active JP7751291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080904A JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080904A Division JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Publications (3)

Publication Number Publication Date
JP2022537685A JP2022537685A (ja) 2022-08-29
JPWO2020252014A5 true JPWO2020252014A5 (enExample) 2023-06-16
JP7751291B2 JP7751291B2 (ja) 2025-10-08

Family

ID=73781275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573428A Active JP7751291B2 (ja) 2019-06-10 2020-06-10 アルファ－ケトグルタル酸塩の持続放出組成物
JP2025080904A Pending JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080904A Pending JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Country Status (11)

Country Link
US (1) US20220265586A1 (enExample)
EP (1) EP3980001B1 (enExample)
JP (2) JP7751291B2 (enExample)
KR (1) KR20220044478A (enExample)
CN (1) CN114126601B (enExample)
BR (1) BR112021024952A2 (enExample)
CA (1) CA3142494A1 (enExample)
DK (1) DK3980001T3 (enExample)
IL (1) IL288782A (enExample)
TW (1) TWI869410B (enExample)
WO (1) WO2020252014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7499259B2 (ja) * 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CN100400042C (zh) 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
JP4169596B2 (ja) * 2000-12-20 2008-10-22 アルコン、インコーポレイテッド 白内障を液化破壊により取り除くための溶液
US20060029668A1 (en) 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
CA2574597A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
MX377119B (es) * 2013-06-06 2025-03-07 Amip Llc Un sistema de dosis no alimenticia suministrable oralmente que comprende hierro y un agente.
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108653221B (zh) * 2015-06-03 2021-09-07 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
KR102643567B1 (ko) 2017-04-25 2024-03-05 버크 인스티튜트 포 리서치 온 에이징 수명 및 건강수명을 연장시키기 위한 제제

Similar Documents

Publication Publication Date Title
JP2021155415A5 (enExample)
TWI750143B (zh) 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
JP2005525369A5 (enExample)
JP2010518122A5 (enExample)
JP2024026244A5 (enExample)
JP2020523335A5 (enExample)
WO2015156581A1 (ko) 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
JP2006505558A (ja) イブプロフェンナトリウムの剤形
JP2024083460A5 (enExample)
MX2007002417A (es) Composiciones de multiparticula farmaceuticas que comprenden acido micofenolico o sodio de micofenolato y composiciones de combinacion de rapamicina.
JP2022116261A (ja) 新規テビペネムピボキシルの即放性および調節放出性経口剤形
JP2022044699A5 (enExample)
JP2002509164A5 (enExample)
JPWO2020252014A5 (enExample)
US20050203115A1 (en) Narcotic-NSAID ion pairs
EP0901372B1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
JP2009534441A (ja) ピリジルメチルスルフィニルベンズイミダゾールのための経口速放医薬製剤
WO2001019350A1 (en) Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US20120003274A1 (en) Oral sustained release antidepressant formulation
WO2020005189A2 (en) Solid oral pharmaceutical compositions comprising teriflunomide
JP2010506855A5 (enExample)
WO2013109225A1 (en) Pharmaceutical tablet formulations comprising ceftibuten
JP2019019112A (ja) ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリル、又はその塩を含む徐放製剤。
AU2006274565B2 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
WO2019209217A2 (en) Modified release formulations of flurbiprofen